IMNN
Imunon IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$12.24M
P/E Ratio
—
EPS
$-6.83
Beta
2.16
52W High
$35.84
52W Low
$2.52
50-Day MA
$3.17
200-Day MA
$5.01
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
16.78
PEG Ratio
5.03
About Imunon Inc
Imunon Inc. is a clinical-stage biotechnology firm focused on pioneering immune-mediated therapies aimed at combating cancer and infectious diseases. Utilizing its proprietary INFECT platform, the company is dedicated to enhancing immune responses that facilitate the effective eradication of malignancies. With a robust pipeline of therapeutics in various stages of clinical evaluation and strategic collaborations that bolster its research capabilities, Imunon is well-positioned to drive notable advancements in immunotherapy, ultimately transforming patient care and establishing a competitive foothold in the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | 125,000 |
| Gross Profit (TTM) | $2.72M |
| EBITDA | $-14.36M |
| Operating Margin | 0.00% |
| Return on Equity | -256.40% |
| Return on Assets | -83.20% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $2.42 |
| Price-to-Book | 1.52 |
| Price-to-Sales (TTM) | 136.97 |
| EV/Revenue | 4.004 |
| EV/EBITDA | 0.91 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.92M |
| Float | $2.59M |
| % Insiders | 0.83% |
| % Institutions | 11.02% |
Analyst Ratings
Consensus ($21.50 target)
3
Buy1
HoldData last updated: 4/8/2026